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Abstract
The Lys(K)153Arg(R) polymorphism in exon 2 (rs1805086, 2379 A.G replacement) of the myostatin (MSTN) gene is a
candidate to influence skeletal muscle phenotypes. We examined the association between the MSTN K153R polymorphism
and ‘explosive’ leg power, assessed during sprint (30 m) and stationary jumping tests [squat (SJ) and counter-movement
jumps (CMJ)] in non-athletic young adults (University students) [n=281 (214 men); age: 21–32 years]. We also genotyped
the MSTN exonic variants E164K (rs35781413), I225T, and P198A, yet no subject carried any of these variant MSTN alleles. As
for the K153R polymorphism, we found only one woman with the KR genotype; thus, we presented the results only for men.
The results of a one-way ANCOVA (with age, weight and height entered as covariates) showed that men with the KR
genotype (n=15) had a worse performance in vertical jumps compared with those with the KK genotype [SJ: vertical
displacement of center of gravity (CG) of 35.1761.42 vs. 39.0660.39 cm, respectively, P=0.009; CMJ: vertical displacement
of CG of 36.4461.50 vs. 40.6360.41 cm, respectively, P=0.008]. The results persisted after adjusting for multiple
comparisons according to Bonferroni. Performance in 30 m sprint tests did however not differ by K153R genotypes. In
summary, the MSTN K153R polymorphism is associated with the ability to produce ‘peak’ power during muscle contractions,
as assessed with vertical jump tests, in young non-athletic men. Although more research is still needed, this genetic
variation is among the numerous candidates to explain, alone or in combination with other polymorphisms, individual
variations in muscle phenotypes.
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Introduction
Some gene polymorphisms are candidates to explain individual
variations in muscle phenotypes. The myostatin (MSTN or growth
differentiation factor 8, GDF8 [MIM601788]) gene [1] is receiving
growing attention in the last years. The MSTN gene encodes
myostatin, a skeletal muscle-specific secreted peptide that functions
mainly to modulate myoblast proliferation and thus muscle mass
and strength [2]. Variants of the MSTN gene are associated with
muscle hypertrophy phenotypes in a range of mammalian species,
most notably cattle [3,4], dogs [5] and mice [2]. A MSTN
polymorphism was recently associated with sprinting ability and
racing stamina in thoroughbred horses [6]. The myostatin-null
mouse model also provides insights into the physiological role of
this protein. Besides its function in reducing sarcopenia [7], it
appears that myostatin also regulates the structure and function of
tendon tissues, as the stiffness of tendons is 14 times higher in
myostatin-deficient mice than in their wild type controls [8].
Variations in the MSTN gene, as well as myostatin inhibition,
can also have functional consequences in humans (see below). The
potential association between MSTN variations and muscle mass
phenotypes is best exemplified in the study by Schuelke et al. [9].
They reported the case of 4-year old child with both copies of the
MSTN gene carrying a mutation (g.IVS1+5gRa transition in the
splice donor site in intron 1) that results in a premature stop codon
and failure to synthesize a mature, functioning protein. The child
exhibited extraordinary muscle development for his age and
precocious physical prowess. Systemic treatment with the
myostatin inhibitor MYO-029 provides an adequate safety margin
and can induce improvements in the muscle strength/function of
adult patients with muscular distrophies [10]. As this type of
treatment would be likely to also stimulate muscle growth in
healthy humans, myostatin manipulation could be among the next
generation of doping in elite sports [11].
Of the identified MSTN variations in humans, the Lys(-
K)153Arg(R) polymorphism located in exon 2 (rs1805086, 2379
A.G replacement) is one candidate to influence skeletal muscle
phenotypes [12]. The Lys(K)153Arg(R) aminoacid replacement is
found within the active mature peptide of the myostatin protein; it
could theoretically influence proteolytic processing with its
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receptor (ActRIIB). The latter results in intracellular activation the
SMAD pathway, through which myostatin induces myoblast
proliferation [13] and differentiation [14], and thus muscle mass
[15]. The frequency of the mutant R allele is of about 3–4%
among Caucasians, with a frequency of mutant homozygotes (RR)
below 1% [12,15,16]. Such low allelic frequency certainly limits
the possibility of studying large groups of people carrying the R
variant. To date, published data on the MSTN K153R
polymorphism and human muscle phenotypes have yield contro-
versial results, partly attributable to inter-ethnic and gender
differences. Kostek et al. [15] recently found an association
between the variant MSTN 153R allele and maximal isometric
contraction of the elbow muscle flexors in African-American
young adults of both genders, yet not in Caucasians. Previous
studies reported no significant effect of MSTN variants on the
muscle mass response to strength training of either Caucasians or
African Americans of both genders, including World-class body-
builders and elite power lifters [12]. Although, in another study
MSTN genotypes did not explain differences in the hypertrophic
response to strength training in adults of both genders, when
women were analysed separately, the 153R allele was associated
with a greater muscle hypertrophic response to training [17]. The
MSTN K153R polymorphism can also affect muscle phenotypes in
the elderly [16,18,19]. For instance, Seibert et al. reported lower
muscle strength in old African American women (n=54, 70–79
years) who carried the variant 153R allele [18].
No study has yet assessed the association between MSTN
genotypes and muscle power during naturally occurring move-
ments, e.g. jumping and sprinting tasks. It was the purpose of our
study to examine the association between the MSTN K153R
polymorphism and ‘explosive’ leg power of non-athletic young
adults, as assessed during specific jumping and sprint tests. We
hypothesized that the 153R allele is associated with decreased
performance in the aforementioned tests. We also genotyped the
MSTN exonic variants E164K (rs35781413), I225T and P198A
because they also seem to cause amino acid replacements in the
gene product (myostatin) expressed in human skeletal muscle [20].
Methods
Ethics statement
The Medical Ethics Committee of Universidad Europea de Madrid
(Madrid, Spain) approved the study design, study protocols and
informed consent procedure. All participants provided written
informed consent.
Subjects
The study sample comprised 281 healthy young adults
(University students) [mean(SD) age: 21(2) years (range: 21, 32)]
of both genders (214 men, 67 women) who took part in a previous
study [21]. Inclusion criteria were to be free of any diagnosed
cardiorespiratory disease, and not to be engaged in competitive
sports such as (i) formal, supervised ‘power’ (e.g. weight lifting or
alpine skiing) or jumping oriented type of training (e.g.
plyometrics, volleyball or basketball) or (ii) endurance training
(e.g. running, swimming of bicycling), that is, performing less than
one (power) or three (endurance) structured weekly training
sessions within the last year. All participants were of the same
Spanish (Caucasian) ancestry for at least 3 generations.
Genotype assessment
Sequences corresponding to the E164K, I225T, K153R and
P198A variants were amplified during Spring 2009 by the
polymerase chain reaction (PCR) in the Genetics Laboratory of
the Universidad Europea de Madrid. The primers used were 59-
GAAAACCCAAATGTTGCTTC-39 and 59-TGTCTAGCT-
TATGAGCTTAGGG-39. The PCR conditions were as follows:
initial denaturing at 95uC 10 min; 35 cycles at 95uC 1 min, 52uC
45 s, 72uC 1 min and a final extension at 72uC 5 min.
The resulting PCR products were genotyped by single base
extension (SBE) [22]. The primers used for E164K, I225T
K153R, and P198A were 59-CAAACACTGTTGTAGGAG-
TCT-39,5 9-CTGAATCCAACTTAGGCA-39,5 9-TTTAATA-
CAATACAATAAAGTAGTAA-39, and 59-TTTTTTTTATCT-
CTGAAACTTGACATGAAC-39 respectively. The PCR SBE
conditions were: 96uC 10 s; 25 cycles at 50uC 5 s and 60uC3 0s .
The resulting PCR products were detected in an ABI PRISM
(Applied Biosystems, Foster City, CA).
Phenotype assessment
Assessment of leg muscle ‘explosive’ power was performed
during spring 2008 in the same location (UEM) and all the tests
were supervised by the same researchers, as detailed elsewhere
[21]. Squat (SJ) and counter-movement jump (CMJ) tests were
performed using an infrared contact timing platform (Globus Ergo
Tester, Codogne `, Italy) to evaluate leg muscles’ ability to produce
‘explosive’ power [23]. Both tests were performed three times
(each separated by a two-minute rest period) and the best score
was retained.
Subjects also performed a 30 m sprint test in an indoor
rubberized track under two conditions: (1) starting from the
stationary (standing) position [23] and (ii) starting with a previous
15 m run (running) thereby allowing achieving higher speeds in
the first meters of the test [24]. The difference in performance time
between both tests (at 15 m and 30 m respectively) was used as an
index of subject’s ability to produce acceleration, i.e. lesser
difference implies higher acceleration capacity. We used photo-
electric gates at 0, 15 and 30 meters to start and stop a digital
timer. We previously showed the reliability of the aforementioned
tests for explosive leg muscle power assessment in a subgroup of
the present subjects [21].
Statistical analysis
We tested Hardy-Weinberg equilibrium using a x
2 test. We
analysed the differences in the study phenotypes among genotypes
(KK vs. KR) of the K153R (rs1805086) polymorphism by one-way
analysis of covariance, where the polymorphism was entered as a
fixed factor, the phenotype was entered as a dependent variable,
and age, weight and height were entered as covariates. We
calculated the effect size statistics as Cohen’s d (standardized mean
differences) and 95% confidence interval [25]. Values of d 0.2, 0.5
and 0.8 are considered small, medium and large effects,
respectively. We used Bonferroni & Holm method to correct for
multiple testing [26]. All statistical analyses were performed using
the PASW (v. 18.0 for WINDOWS, Chicago).
Results
We detected no failures in sample collection and DNA
acquisition. Genotyping success rate was .99.29% (two missing
data, one man and one woman).
Genotype distributions met Hardy-Weinberg equilibrium
(P=0.59). No subject carried the variant alleles E164K, I225T,
or P198A. We found only one woman with the KR genotype; thus,
we present the results only for men. Table 1 shows the association
between the K153R polymorphism and study phenotypes in men.
We observed that men with the KR genotype had a worse
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with the KK genotype. The results persisted after adjusting for
multiple comparisons. The variance explained ranged from 5 to
10%. Effect size statistics, as measured by the Cohen’s d, indicated
a medium effect size. Performance in sprint tests did not differ by
K153R genotypes.
Discussion
The main, novel finding of our study was that the variant 153R
allele of the MSTN K153R polymorphism is associated with
decreased jumping performance in young non-athletic men.
Sprinting (running) ability was however unaffected by the MSTN
K153R genotypes. Although more research is needed, and while
keeping in mind that exercise-related phenotypes are likely
polygenic, our data give support for a role of the MSTN K153R
polymorphism in explaining, at least partly, individual variations
in the humans’ capacity for muscle ‘peak’ power generation. In
contrast, in the present cohort of subjects we previously found no
association between performance in the jump/sprint tests and the
R577X polymorphism in the gene (ACTN3) encoding a-actinin-3
[21]. This variation is thought to play an important role in the
muscles’ ability to produce high power, at least in elite athletes
[27].
We assessed ‘explosive’ muscle power by means of jumping and
sprinting tests, which are naturally occurring multi-joint move-
ments in humans that involve the coordinated participation of the
majority of lower limb muscles [28,29]. We believe this is in fact a
strength of our study versus previous research in the field of
genetics and exercise-related phenotypes that used other tests for
muscle power assessment, for instance, maximal concentric muscle
work during single-joint movements (e.g. flexor elbow contrac-
tions) at relatively low angular velocities (#120u?s
21) [30].
However, during actual natural high muscle power actions such
as the sprint and jumps performed by our subjects, angular
velocities at the hip or knee joints can approach 800–1000u?s
21
[31]. To note is that our findings are partly limited by the fact that
we did not assess muscle mass in our cohort, and therefore we
could not determine whether the influence of MSTN K153R
genotypes on muscle power is mediated by its expected effects on
muscle mass. Finally, the finding that the MSTN K153R
polymorphism was associated with vertical jump performance
but not with sprint performance warrants further investigation.
Although both tests are thought to determine muscle power
performance, stationary jumps and running sprints are determined
by different factors. The critical factor during running sprints,
owing to the short duration of the foot contact on the ground, is
the rate of force development, which in turn is determined by
many factors such as muscle fibre type, synchronization of motor
units, tendon stiffness, or lean mass of lower extremities [32]. In
contrast, the ability of leg muscles (quadriceps) to produce power
during the concentric phase of muscle contraction is the main
factor affecting stationary vertical jumps as the ones we used here
[33]. The elastic properties of tendons can also influence jump
ability, at least in the case of CMJ. Compared with a stiffer muscle
tendon complex (MTC), people with a more compliant MTC
should be more efficient in utilizing elastic strain energy during
jumps [34,35]. The fact that our KR subjects showed worst
jumping performance than their wild-type KK counterparts could
be associated, at least partly, with a potential role of myostatin in
tendon structure. Myostatin-deficient mice showed indeed 14
times higher tendon stiffness than wild-type mice [8]. Further
research is needed to determine the possible association between
MSTN polymorphisms and tendon characteristics in humans. Up
to date, published data on the MSTN K153R polymorphism and
human muscle phenotypes (at baseline or in response to training)
have yield controversial results, at least in adults of young or
medium age. Inter-ethnic differences in allele frequencies, gender-
related differences and the low allelic frequency of the 153R allele
(limiting the possibility of studying large groups of people carrying
the R variant) are important reasons for controversy. Kostek et al.
[15] recently found an association between the MSTN 153R allele
and maximal isometric contraction of the elbow muscle flexors in a
group of 23 African-American young adults of both genders, yet
Table 1. Mean estimates of study phenotypes by genotypes of the K153R (rs1805086) polymorphism in the GDF8 gene in men.
KK (n=201) KR (n=15) P R
2 Cohen’s d (95%CI)
Vertical Jump Tests
SJ
Flight time (s) 563.09 (38.95) 533.94 (43.13) 0.007 0.100 0.74 0.461–1.014
Vertical displacement of CG (cm) 39.06 (5.44) 35.17 (5.49) 0.009 0.095 0.71 0.431–0.983
CMJ
Flight time (s) 574.35 (39.62) 543.29 (46.20) 0.005 0.057 0.76 0.483–1.038
Vertical displacement of CG (cm) 40.63 (5.67) 36.44 (5.92) 0.008 0.053 0.72 0.446–0.999
Sprint Tests
30m running start
Time at 15 m (s) 1.92 (0.14) 1.91 (0.08) 0.684 0.049 0.11 20.159–0.378
Time at 30 m (s) 3.76 (0.21) 3.75 (0.17) 0.987 0.065 0.00 20.263–0.273
30m standing start
Time at 15 m (s) 2.54 (0.12) 2.56 (0.13) 0.533 0.002 20.17 20.436–0.101
Time at 30 m (s) 4.41 (0.19) 4.44 (0.23) 0.559 0.014 0.16 20.111–0.425
Values are means (standard deviation).
P values related to group differences (one way analysis of covariance after adjusting for age, weight and height).
Cohen’s d (standardized mean differences) and 95% confidence interval (CI). Values of d 0.2, 0.5 and 0.8 are considered small, medium and large effects, respectively.
Abbreviations: SJ, squat jump; CMJ, counter-movement jump; CG, centre of gravity.
doi:10.1371/journal.pone.0016323.t001
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Caucasian young adults (n=509, also men and women). Maximal
dynamic contraction (one repetition maximum) was also unaffect-
ed by MSTN genotypes in both cohorts. Ferrell et al. [12] reported
no significant effect of the MSTN variants we studied here on the
muscle mass response to strength training in either Caucasians or
African Americans (n=153 men and women). In another study
[17], MSTN genotypes did not explain differences in the
hypertrophic response to strength training in 32 adults (age range:
21–75 years) of both genders studied as a group; yet, when women
were analyzed separately the 153R allele was associated with a
68% larger increase in muscle volume in response to training.
Thomis et al. [30] reported similar values in elbow flexor strength
at baseline or in response to training in a young adult with the
153KR genotype compared with those with the 153KK genotype.
Evidence for the putative influence of the MSTN K153R
polymorphism on muscle phenotypes is probably stronger in the
elderly [16,18,19]. Notably, in a cohort of old African American
women (n=54, 70–79 years). Seibert et al. [18] reported lower
muscle strength (hip and knee flexion and handgrip strength
combined) in those who carried the 153R allele. We recently
reported lower muscle mass/function in a very old woman (age 96
years) with the very rare MSTN 153RR genotype compared to her
age-matched referents with the 153KK genotype [19].
Although more research is needed, the putative effect of the
K153R polymorphism on muscle phenotypes is due to its potential
to alter the function of the MSTN gene [12]. Myostatin enters the
bloodstream as a latent precursor protein; it then undergoes a
proteolytic process to become a mature peptide (free from the
propeptide) that binds to extracellular activin type II receptor
(ActRIIB) [15]. Binding of myostatin to ActRIIB induces
intracellular activation of SMAD proteins and, through the
SMAD pathway, myostatin modulates myoblast proliferation
[13] and differentiation [14], and thus ultimately muscle mass
[15]. The Lys(K)153Arg(R) aminoacid replacement is found
within the active mature peptide of the myostatin protein, and
could theoretically influence (i) proteolytic processing with its
propeptide or (ii) affinity to bind with ActRIIB [36,37]. This in
turn would result in inability of myostatin to modulate muscle
mass/power [15].
In summary, the MSTN K153R polymorphism is associated
with the ability to produce ‘peak’ power during muscle
contractions, as assessed with vertical jump tests, in young non-
athletic men. Thus, although more research is still needed, this
polymorphism is among the numerous candidates to explain,
alone or in combination with other polymorphisms, individual
variations in muscle phenotypes.
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